Abstract
This nonrandomized controlled trial used a 1-to-1 therapist-to-patient ratio to administer psilocybin to groups of patients with cancer who were diagnosed with major depression disorder to create a scalable, rapidly effective depression treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have